Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19

IMPORTANCE: Monoclonal antibody (mAb) treatment decreases hospitalization and death in high-risk outpatients with mild to moderate COVID-19; however, only intravenous administration has been evaluated in randomized clinical trials of treatment. Subcutaneous administration may expand outpatient treat...

Descripción completa

Detalles Bibliográficos
Autores principales: McCreary, Erin K., Bariola, J. Ryan, Wadas, Richard J., Shovel, Judith A., Wisniewski, Mary Kay, Adam, Michelle, Albin, Debbie, Minnier, Tami, Schmidhofer, Mark, Meyers, Russell, Marroquin, Oscar C., Collins, Kevin, Garrard, William, Berry, Lindsay R., Berry, Scott, Crawford, Amy M., McGlothlin, Anna, Linstrum, Kelsey, Nakayama, Anna, Montgomery, Stephanie K., Snyder, Graham M., Yealy, Donald M., Angus, Derek C., Kip, Paula L., Seymour, Christopher W., Huang, David T., Kip, Kevin E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006104/
https://www.ncbi.nlm.nih.gov/pubmed/35412625
http://dx.doi.org/10.1001/jamanetworkopen.2022.6920

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006104/
https://www.ncbi.nlm.nih.gov/pubmed/35412625
http://dx.doi.org/10.1001/jamanetworkopen.2022.6920

Ejemplares similares